Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3816 MET exon 14 skipping mutation – A new potential therapeutical target for lung carcinoids? Results from a next-generation sequencing (NGS) study

Introduction: Lung NETs, classified as typical carcinoid (TC) and atypical carcinoid (AC), share the well-differentiated morphology, but are characterized by an extreme heterogeneity in terms of biological aggressiveness and outcomes. Unfortunately, to date a unique molecular classification of these tumors is lacking, and therefore no personalized treatments are available.

Conference:

Presenting Author: La Salvia A

Authors: La Salvia A, Melucci E, Ciuffreda L, Resuli B, Visca P,

Keywords: lung neuroendocrine tumor, molecular profile, Oncomine Focus panel, MET exon 14 skipping mutation, therapeutic target,

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,

#2202 Assessment of the Clinical Utility of the NETest in a US Registry-Based Study

Introduction: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancer. Current biomarkers in NET disease have limited clinical utility.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Bodei L

Authors: Liu E, Paulson S, Gulati A, Freudman J, Grosh W,

Keywords: Registry, biomarker, NETest, GEP-NET, Monitor, Treatment, Predict,